Redwood Pharma AB (REDW.ST) Research

Redwood Pharma AB focuses on creating pharmaceutical treatments for eye-related conditions, addressing medical needs that currently lack effective solutions. The company's leading product in development is RP101, an eye drop designed to treat severe and persistent dry eye disease, specifically targeting post-menopausal women. They employ IntelliGel, an advanced supramolecular smart drug delivery system, to develop topical formulations for various ophthalmic uses and to deliver treatments directly to the eye's surface. Redwood Pharma AB is based in Stockholm, Sweden.

Market snapshot

Symbol
REDW.ST
Price
$1.19
Day change
0.00%
Market cap
$3.1M
P/E ratio
-0.00x
52-week range
0.03-5.22
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Asarina Pharma AB (publ) (ASAP.ST)
  • Bioservo Technologies AB (publ) (BIOS.ST)
  • Bonzun AB (publ) (BONZUN.ST)
  • Cline Scientific AB (publ) (CLINE-B.ST)
  • Cyxone AB (publ) (CYXO.ST)
  • Duearity AB (publ) (DEAR.ST)
  • Scandion Oncology A/S (SCOL.ST)
  • Ziccum AB (publ) (ZICC.ST)

Open Redwood Pharma AB (REDW.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.